Fig. 7

Establishment of patient-derived primary and recurrent glioma stem cell spheres (GSCs). A The expression of TRAF7 in primary and recurrent patient-derived glioma cells with or without knockdown. B IC50 of Lomustine (CCNU) in primary and recurrent glioma stem cells. C Cell viability of primary and recurrent patient-derived glioma cells treated with lomustine (50 μM). D Brightfield image of GSC spheres in Matrigel (scale bar = 100 µm). E The radar chart provides a comprehensive comparison of different cells, including the inhibitory efficiency of combined therapy, tumor sphere size, CD133 expression levels, and migration capacity. F Evaluation of the GSCs formation ability between the control group and si-TRAF7 group treated with or without CCNU (scale bar = 100 µm). G The primary and recurrent glioma stem cells were stained with stem cell markers (CD133) (scale bar = 100 µm). H Transwell assays of pGSC#3 and rGSC#1 (scale bar = 50 µm). I Heat map of three primary glioma patients and one recurrent glioma patient with clinical characteristics